Page 38 - TD-2-2

Tumor Discovery A comprehensive review of bexarotene

9.2.2. Process for the preparation of high-purity Bexarotene is a diamond in the rough, as its
bexarotene (2011) multipotentiality has not yet been fully recognized by
Assigned to: “Ind-Swift Laboratories Limited” WO2011141928A1 many researchers. Therefore, future investigations should
focus on gathering more information and emphasizing the
The invention stipulates an economically feasible development of novel formulations for this drug. It has the
method for preparing a pure form of bexarotene. It also potential to emerge as an effective and broad-spectrum
discloses the method of identification and extraction of anticancer drug, capable of treating even incurable
impurities using chromatographic analysis. The invention malignancies. Moreover, with rapid mutations in the
claims to produce a pure form of bexarotene containing SARS-CoV-2, there is an urgent need to deploy this drug
impurities <0.15% and unidentified impurities <0.10%, as in various clinical trials and animal models. Bexarotene
[74]
identified by high-performance liquid chromatography . exhibits a higher affinity for and interactions with the
9.2.3. Bexarotene analogs (2011) ACE2 receptor and the main SARS-CoV-2 proteases than
other anti-viral drugs.
Assigned to: “Arizona Board of Regents of ASU” US9174917B2
This patent reveals novel analogs of bexarotene and Acknowledgments
their methods of use. The invention claims that these None.
newly developed analogs can be used as a treatment option
for hyperproliferative disorders, including cancers such Funding
as lymphoma, sarcoma, or leukemia. Furthermore, these None.
compounds show potential for combating myeloma of
reproductive systems. The patent also declares that these Conflict of interest
analogs can be advantageous in treating other medical
conditions such as hypertriglyceridemia, hyperlipidemia, The authors declare no conflict of interest.
dyslipidemia, hypercholesterolemia, vascular diseases, Author contributions
cardiovascular diseases, and atherosclerosis. The invented
analogs have demonstrated promising cytotoxic and Conceptualization: Ayushi Mahajan, Lovepreet Singh,
apoptotic properties . Gurjeet Singh, Ravi Kumar Dhawan, Manjeet Kaur,
[75]
Lakhvir Kaur
10. Conclusion and future perspectives Writing - original draft: Ayushi Mahajan, Lovepreet Singh,
Bexarotene is a promising newly engineered chemical Manjeet Kaur, Pritpal Kaur Malhi, Komal Thakur
moiety with potential for treating various disorders. Writing - review and editing: Ayushi Mahajan, Lovepreet
Particularly noteworthy is its enhanced potency and Singh, Manjeet Kaur, Pritpal Kaur Malhi, Komal
reduced toxic effects when used in concomitant therapy Thakur
with other targeted drugs. The combined results of various Ethics approval and consent to participate
clinical studies highlight the effectiveness of bexarotene
as a robust antineoplastic agent, capable of reducing the Not applicable.
expression of tumor-promoting genes such as epidermal
growth factor receptor, BCRP, COX-2, and others. Consent for publication
Furthermore, bexarotene has been shown to be safe when Not applicable.
used conjugately with skin-directed therapies like PUVA.
However, its poor aqueous solubility and bioavailability are Availability of data
the stumbling blocks in formulating the drug. Therefore, Not applicable.
robust actions are required to explore and maximize
its potential, and novel approaches should be devised to References
enhance its efficacy and safety. Studies indicate that the
clinical application of bexarotene in CTCL is of prime 1. Li L, Liu Y, Wang J, et al., 2014, Preparation, in vitro and
concern, but beyond cancer, it holds excellent potential in vivo evaluation of Bexarotene nanocrystals with surface
modification by folate-chitosan conjugates. J Drug Deliv,
for treating fatal disease like COVID-19. Robust in vivo 23(1): 79–87.
studies and clinical trials are needed to further investigate
its application in these areas. In conclusion, bexarotene https://doi.org/10.3109/10717544.2014.904455
warrants more attention due to its multiple applications in 2. Zhang C, Hazarika P, Ni X, et al., 2002, Induction of
various cancer types, CNS disorders, and other ailments. apoptosis by Bexarotene in cutaneous T-cell lymphoma

Volume 2 Issue 2 (2023) 12 https://doi.org/10.36922/td.0436